Toby Maher, Royal Brompton Hospital, London, met with us at ERS 2019 in Madrid to discuss the results of a Phase II trial of pirfenidone in patients with progressive fibrosing unclassifiable ILD (uILD).
1. What is the definition of unclassifiable interstitial lung disease (uILD) and what proportion of ILD patients are considered unclassifiable? (0:05)
2. What is the current standard of care for patients with progressive fibrosing uILD? (0:44)
3. Could you tell us a little about the design and findings of the recent study investigating pirfenidone in patients with progressive fibrosing uILD? (1:11)
4. Which patients are most likely to respond to this treatment approach? (1:55)
5. What further studies are planned? (2:33)
Speaker disclosures: Toby Maher has received consultancy fees, travel expenses and honoraria from Roche and Boehringer Ingelheim.
touchRESPIRATORY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Filmed at the European Respiratory Society (ERS) International Congress 2019, Madrid, Spain.
Share this Video
Related Videos In Interstitial Lung Disease
Clinical trials and current standard of care in idiopathic pulmonary fibrosis: Steven D. Nathan, ATS 2023
Idiopathic pulmonary fibrosis (IPF) is a serious chronic lung disease which results in symptoms such as shortness of breath and dry cough and is caused by fibrosis of the lungs. It was a pleasure to talk with Dr. Steven D. Nathan (Inova Fairfax Hospital, Falls Church, VA, USA) to discuss the incidence, prognosis and pathology of […]
TETON-1 & -2 phase 3 studies of treprostinil in IPF – baseline characteristics: Steven D. Nathan, ATS 2023
The TETON program consists of two currently recruiting phase 3 randomized, double-blind, placebo-controlled studies that are investigating the efficacy and safety of inhaled treprostinil in idiopathic pulmonary fibrosis (NCT04708782, NCT05255991). It was a pleasure to talk with Dr. Steven D. Nathan (Inova Fairfax Hospital, Falls Church, VA, USA) around the aims and design of the TETON program […]
Jean Elwing, CHEST 2022: Inhaled treprostinil for pulmonary hypertension due to interstitial lung disease – the INCREASE OLE study
INCREASE OLE was the open-label extension of the INCREASE study (NCT02630316), which investigated the safety and efficacy of inhaled treprostinil in patients with pulmonary hypertension due to interstitial lung disease. We caught up with Prof. Jean Elwing (UC Health, Cincinnati, OH, USA) to discuss the methodology, inclusion criteria, and safety and tolerability findings from the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!